Dyne Therapeutics Inc. shares surged more than 40% after people with knowledge of the matter said the developer of drugs to treat muscle diseases has received takeover interest from larger pharmaceutical companies. The Waltham, Massachusetts-based company has been speaking with advisers as it considers options including a possible sale or partnership, according to the people, who asked not to be identified discussing confidential information.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.2 USD | -4.42% |
|
+6.14% | +215.64% |
07-09 | JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating | MT |
07-01 | Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Small Cap Comp Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+215.64% | 4.38B | |
+21.74% | 47.96B | |
+0.70% | 42.45B | |
+43.96% | 41.47B | |
+25.73% | 31.6B | |
+20.65% | 28.63B | |
-4.47% | 28.03B | |
+51.59% | 14.56B | |
+45.25% | 14.14B | |
+2.37% | 12.58B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Dyne Therapeutics Reportedly Seeing Takeover Interest, Weighing Options